Mgr. Marek Borský
Researcher, Department of Internal Medicine, Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
phone: | +420 532 23 4830 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 125
2019
-
Peripheral blood of CLL patients is repopulated with complement resistant malignant cells one day after rituximab infusion: possible implications for subsequent chemotherapy.
Year: 2019, type: Conference abstract
-
Potenciál inhibice proteinu checkpoint kinase 1 u chronické lymfocytární leukémie s mutacemi v genu TP53.
Year: 2019, type: Conference abstract
-
Potenciál inhibice proteinu CHK1 u chronické lymfocytární leukemie s mutacemi v genu TP53
Year: 2019, type: Conference abstract
-
Promoter Methylation of ROR1 Ligand WNT5A associates with Its Expression in Chronic Lymphocytic Leukemia
Year: 2019, type: Conference abstract
2018
-
CD20 is a direct regulator of B-cell receptor signaling in the microenvironment of chronic lymphocytic leukemia
Year: 2018, type: Conference abstract
-
CD20 reguluje signalizaci přes B-buněčný receptor v mikroprostředí chronické lymfocytární leukémie
Year: 2018, type: Conference abstract
-
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo
Year: 2018, type: Conference abstract
-
Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience
Year: 2018, type: Conference abstract
-
Genetické aberace a doba do progrese onemocnění u pacientů s CLL léčených režimy FCR nebo BR v 1. linii
Year: 2018, type: Conference abstract
-
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53
Year: 2018, type: Conference abstract